Compounds > l 163255
Page last updated: 2024-12-08

l 163255

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 163255: a growth hormone secretagogue; RN given for (R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID196958
CHEMBL ID107751
SCHEMBL ID5015356
MeSH IDM0267498

Synonyms (13)

Synonym
l 163255
l-163255
CHEMBL107751
2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-5-phenylpentan-2-yl]propanamide
l-163,255
159634-54-5
l 163,255
n-(1-(1,2-dihydro-1-methanesulfonylspiro(3h-indole-3,4'-piperidine-1'-yl)carbonyl)-4-phenylbutyl)-2-amino-2-methylpropanamide hydrochloride
SCHEMBL5015356
DTXSID50166701
PD161188
AKOS040752293
propanamide, 2-amino-n-[(1r)-1-[[1,2-dihydro-1-(methylsulfonyl)spiro[3h-indole-3,4'-piperidin]-1'-yl]carbonyl]-4-phenylbutyl]-2-methyl-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID209316Compound was measured for IGF-1 increases in swine on days 4, 7, 10, and 14 approximately1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID209317Compound was measured for elevated mean plasma IGF-1 (insulin like growth factor) concentrations in Swine1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID61096Loss of body weight in dog is evaluated after compound was administered perorally to dog at a dose 5 mg/kg, once daily (control (wt) = 1.13+/-0.19)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID228874The intrinsic potency studied extensively in animals1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (38.46)18.2507
2000's7 (53.85)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (23.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
l 692429
L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source		4.3130
l 163191
[no description available]		3.0910
ibutamoren mesylate
ibutamoren mesylate: a growth hormone secretagogue; structure in first source		3.1210
hexarelin
hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6		3.5320
l 692585
[no description available]		3.0910peptide
sk&f 110679
[no description available]		3.0910
ghrp-1
alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide: amino acid sequence given in first source; a second generation growth hormone-releasing peptide		3.0910
cortistatin 14
cortistatin: a cortical neuropeptide; shows strong structural similarity to somatostatin; a neuronal depressant; has sleep-modulating activity; amino acid sequence given in first source		2.0310
piperidines
Piperidines: A family of hexahydropyridines.		5.49120
ConditionIndicatedRelationship StrengthStudiesTrials
Uremia
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.		02.0110
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0210
Dwarfism, Growth Hormone Deficiency
[description not available]		02.0210
Dwarfism, Pituitary
A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.		02.0210
Intertrochanteric Fractures
[description not available]		02.9410
Hip Fractures
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).		02.9410
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9910
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		01.9910
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9910